Schedule I · possession unlawful
Kansas lists psilocybin and psilocyn in Schedule I. Knowing possession remains unlawful under K.S.A. 21-5706.

KS legal and access quick reference
Reviewed on September 28, 2026 by iMD teamA concise, source-dated explanation of statewide law, regulated access, and the difference between state and local policy.
Laws and implementation can change quickly. This page is educational information, not legal advice.
Kansas lists psilocybin and psilocyn in Schedule I. Knowing possession remains unlawful under K.S.A. 21-5706.
Kansas has no enacted personal-use, retail, dispensary, or supervised-service program for psilocybin.
HB 2218 advanced in 2026 and remains pending. It would create a narrow future pathway for a specified FDA-approved crystalline-polymorph psilocybin pharmaceutical by placing that approved product in Schedule IV after FDA approval and state certification. It would not create mushroom, retail, personal-use, or service-center access.
HB 2218 received a favorable House Health and Human Services Committee recommendation in January 2026 and is on General Orders in the House. The proposal is narrowly focused on a future FDA-approved crystalline-polymorph psilocybin drug product: after FDA approval and state certification, that specific pharmaceutical would be placed in Schedule IV. The bill does not create general psilocybin legalization or a public psilocybin-services program.
For Kansas City, Topeka and Wichita, this Kansas page is the appropriate quick-reference starting point because no separate municipal action was retained as a distinct local-policy guide. Local rules can change, so verify current official records.
The statewide explanation above covers Kansas City, Topeka and Wichita. A separate page appears below only where a documented municipal action adds material local context.
This page was checked against the controlling state statutes, enacted laws, agency records, and official bill histories listed below.
No. Psilocybin and psilocyn remain Schedule I substances, and unauthorized possession remains unlawful.
No. Kansas has no enacted personal-use, retail, dispensary, or supervised-service program. HB 2218 remains a proposal and does not create current access.
HB 2218 received a favorable House committee recommendation in January 2026. If enacted, it would create a future Schedule IV pathway only for a specified FDA-approved crystalline-polymorph psilocybin pharmaceutical after the required certification. The bill remains pending and does not create current public access.
No. A local enforcement-priority policy may affect municipal enforcement, but it does not legalize commercial sale, create statewide legality, or override federal law.
The product-site link provides product-format and business-policy information. It does not change the law described on this page or establish legal access in any jurisdiction.